(UroToday.com) The Society of Urologic Oncology (SUO) 2021 annual winter meeting included a prostate cancer session and a presentation by Dr. Andrew Armstrong discussing a post-hoc analysis of the ARCHES trial assessing the extended efficacy of enzalutamide plus ADT on oligometastatic hormone-sensitive prostate cancer. In ARCHES, enzalutamide + ADT reduced the risk of radiographic progression and improved secondary clinical outcomes in patients with metastatic hormone-sensitive prostate cancer (mHSPC) over placebo + ADT.1 A previous post hoc analysis demonstrated the efficacy of enzalutamide + ADT on bone-only oligometastatic disease but excluded soft tissue disease to control for the influence of variable metastatic spread. However, soft tissue metastases are often present in oligometastatic HSPC patients with or without bone metastases. Therefore, it is important to assess their influence on the disease and clinical outcomes. This extended post hoc analysis evaluated the efficacy of enzalutamide + ADT in patients with oligometastatic HSPC compared to polymetastatic HSPC in the ARCHES overall intent-to-treat (ITT) population, which included those with bone, soft tissue, or both types of metastases.